Axi-Cel Improves QoL in Second-Line Treatment of LBCL
December 12th 2021Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, resulted in clinically meaningful improvement in quality of life at day 100 compared with standard of care as a second-line treatment of patients with relapsed/refractory large B-cell lymphoma.
Read More
Tisagenlecleucel Displays Promising Efficacy Results Across Subgroups in R/R FL
December 11th 2021Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.
Read More
Liso-cel Bests Standard of Care in Second-Line Treatment of LBCL
December 11th 2021Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.
Read More
Adjuvant Pembrolizumab Sustains Benefit Across TNBC Subgroups
December 7th 2021Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in event-free survival in patients with early-stage triple negative breast cancer.
Read More
Investigators Aim to Identify New Treatment Targets with Cancer Cell Map Initiative
November 16th 2021The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.
Read More
Novel ADC Appears to Leverage TROP2 Expression in NSCLC
November 16th 2021Investigators aim to expand the treatment portfolio with the phase 3 TROPION-LUNG01 trial, which is designed to examine datopotamab deruxtecan vs docetaxel in patients with advanced or metastatic NSCLC without actionable genomic alterations who have previously received platinum-based chemotherapy and immunotherapy.
Read More
Lenvatinib Plus Pembrolizumab Displays Strong Efficacy in Advanced Endometrial Cancer
November 15th 2021The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).
Read More
Treatment Options Continue to Increase in Low-Risk MDS
November 3rd 2021Azanucleosides, such as azacitidine, remain the backbone of disease-modifying therapy for patients with myelodysplastic syndromes, however, new adjuncts are leading to longer remissions and disease-free survival in patients with low-risk disease.
Read More
Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial
October 14th 2021The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.
Read More
Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in Multiple Myeloma Treatment
September 27th 2021Patients with relapsed/refractory multiple myeloma, particularly those who have failed a prior BCMA–targeted therapy, represent a population with an unmet need for effective treatment options. Investigators are hoping to help fill this void with the initiation of the phase 2 MagnetisMM-3 study.
Read More
LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
September 14th 2021Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.
Read More
Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer
September 11th 2021Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.
Read More